Funder: Cancer Research Institute
Due Dates: December 1, 2025: Initial Protocol Concept deadline | April 4, 2026: Invited Full Proposal deadline
Funding Amounts: Up to $1,000,000 per trial (plus up to 10% indirect costs); typically supports 1–2 years.
Summary: Funds academic-led, innovative phase I/II or phase II immunotherapy clinical trials to advance novel treatments and deepen understanding of cancer immunology.
Key Information: No citizenship restrictions; research must be at non-profit institutions (US or international); two-stage application process.